WellTheory Raises $14 Million Series A Led by General Catalyst to Expand AI-Driven Autoimmune Care Platform

WellTheory, a San Francisco-based virtual care company focused on autoimmune disease, has announced new funding and expansion plans aimed at scaling its AI-enabled, whole-person care model. According to company disclosures, WellTheory raised US $14 million in a Series A financing round led by General Catalyst, with participation from investors including 7wire Ventures, Ingeborg Investments, Accel, Box Group and Up2 Opportunity Fund. The Series A brings WellTheory’s total funding to approximately US $26.2 million.

In addition to the Series A, WellTheory had previously raised approximately US $7.2 million in a seed round that was led by Accel and included backers such as Box Group, Lux Capital, Rock Health, Scribble Ventures and others. Later, in mid-2025 the company also closed a US $5 million capital raise involving new investors such as Samsung Next, Opal Ventures and Up2 Fund alongside continuing support from Accel, Box Group and OVO Fund.

WellTheory was founded with a mission to address the unmet needs of more than 50 million Americans living with autoimmune conditions, the vast majority of whom are women, by offering a personalized, evidence-based care program rather than simply symptom management. The company leverages a mix of lifestyle medicine, nutrition, coaching, and technology — including its proprietary AI tools “Care Hub” and “Care Scribe” — to streamline workflows, surface insights and personalize care for patients managing conditions such as lupus, rheumatoid arthritis, Hashimoto’s, Crohn’s disease and others.

The company said it will deploy the new Series A funds to fuel commercial growth — expanding its programs into employers and health plan partnerships — and accelerate the development of its AI technology stack. Early traction includes partnerships with employers and payers, where the value proposition centers on improving member outcomes and reducing high-cost specialty care for autoimmune disease. WellTheory reports that its platform has achieved significant improvements in outcomes and cost savings, such as reductions in fatigue, pain and use of specialty medications, as it broadens into enterprise segments.

In describing the seed round launch, WellTheory highlighted that its founding team included individuals with lived experience of autoimmune disease, driving its mission to create a care model informed by that firsthand perspective. The company said it operated in private beta before publicly announcing the seed financing, and built its initial consumer offering while validating its model with members before scaling.

The earlier US $5 million raise in mid-2025—targeted toward accelerating the AI-enabled aspects of its platform and entering the employer/health-plan market—coincided with the rollout of Care Hub and Care Scribe. According to the company, Care Scribe functions as an AI assistant that transcribes provider-member conversations, drafts follow-up notes and personalized care plans; Care Hub acts as a centralized dashboard that aggregates lab results, session history, member data and supports workflow and compliance automation. With those tools deployed, the company says it is now positioned to deepen personalization, scale operations and integrate more comprehensive data streams.

WellTheory’s commercial ambitions address a dual challenge: enabling employers and payers to manage rising costs associated with autoimmune conditions (including specialty pharmaceuticals and productivity losses) and providing a more holistic, root-cause-oriented care experience for patients who often face long diagnostic journeys and fragmented care. With 80 % or more of autoimmune patients being women, the company also emphasizes its women’s-health program launched in 2024, which targets the intersection of hormone, metabolic and autoimmune conditions.

While WellTheory enters this growth phase, it will face typical challenges of scaling a care-platform business in the healthcare space: integrating with employer benefits and payer systems, demonstrating long-term health and economic outcomes at scale, expanding its provider network, and managing provider workflow alongside AI tools. Achieving sustainable recurring revenue from enterprise contracts and proving the health-economic value of its offerings will be critical.

By raising US $14 million in Series A now, WellTheory positions itself to advance commercial partnerships, deepen its AI infrastructure and further its mission of “reversing the autoimmune epidemic” by delivering personalized, root-cause care at scale for a condition set that has historically been underserved.